Inventiva (NASDAQ:IVA) Raised to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen upgraded Inventiva to a "hold" rating, signaling a change in outlook for the company.
• Guggenheim and HC Wainwright both issued "buy" ratings with increased price targets for the stock, indicating positive sentiment among analysts.
• Inventiva's stock has shown variability, having a one-year low of $2.11 and a one-year high of $6.55, with current trading around $4.85.

Inventiva (NASDAQ:IVA - Get Free Report) was upgraded by Wall Street Zen to a "hold" rating in a research note issued on Saturday.

A number of other research firms have also issued reports on IVA. Guggenheim upped their target price on Inventiva from $9.00 to $13.00 and gave the company a "buy" rating in a research note on Tuesday, September 2nd. HC Wainwright increased their price target on Inventiva from $20.00 to $24.00 and gave the stock a "buy" rating in a research note on Thursday, October 9th. Canaccord Genuity Group reissued a "buy" rating and set a $20.00 price target on shares of Inventiva in a research note on Tuesday, September 30th. Weiss Ratings reissued a "sell (d-)" rating on shares of Inventiva in a research note on Wednesday, October 8th. Finally, Piper Sandler began coverage on Inventiva in a research note on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $16.14.

Inventiva Price Performance

IVA stock opened at $4.85 on Friday. Inventiva has a 1 year low of $2.11 and a 1 year high of $6.55. The stock's 50 day moving average price is $5.28 and its 200 day moving average price is $4.00.

Institutional Trading of Inventiva

An institutional investor recently raised its position in Inventiva stock. Wealth Enhancement Advisory Services LLC boosted its stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) by 54.5% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,558 shares of the company's stock after purchasing an additional 5,843 shares during the period. Wealth Enhancement Advisory Services LLC's holdings in Inventiva were worth $50,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 19.06% of the company's stock.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.